EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Shikonin-Loaded ROS-Responsive Microneedles for Psoriasis Therapy: Formulation, Transdermal Delivery, and Mechanistic Evaluation

Haoran Cheng iD, Jiaqin Dai, Lulu Cheng, Hao Liang, Yuji Zhuang, Huishan Xu, Xingxian Ou, Jun Shi

Pharmaceutics · 30.07.2026 · 18 (8) · 939

DOI: 10.3390/pharmaceutics18080939 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 30.07.2026. Verfasst von Haoran Cheng und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Chinese Materia Medica, Guangdong Pharmaceutical University, Guangzhou 510006, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Guangdong Natural Science Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Shikonin (SKN) is a potential anti-psoriatic agent, yet its clinical application is hindered by poor water solubility and low stratum corneum permeability. This study aimed to develop a reactive oxygen species (ROS)-responsive hydrogel microneedle system encapsulating SKN-loaded polymeric micelles (SKN-M@MN) to enhance transdermal delivery and evaluate its therapeutic effects in psoriasis.

Methods

Shikonin-loaded micelles (SKN-M) were optimised using a thin-film hydration method. SKN-M@MN was fabricated via a two-step casting method using phenylboronic acid-modified hyaluronic acid (HA-PBA) and polyvinylpyrrolidone K90 as the tip matrix. Skin penetration, ROS-responsive release, and anti-psoriatic efficacy were assessed in an imiquimod (IMQ)-induced mouse model. Mechanistic studies included RNA-seq, qPCR, and Western blotting.

Results

SKN-M achieved an encapsulation efficiency of 93.45 ± 0.24%, a particle size of 62.49 ± 0.92 nm, and a zeta potential of −36.78 ± 1.12 mV. SKN-M@MN showed 100% skin penetration, sustained drug release, and accelerated degradation under high ROS conditions. In psoriatic mice, SKN-M@MN significantly alleviated skin lesions, reduced epidermal hyperplasia (Ki67), and downregulated IL-17A and TNF-α levels both locally and systemically. Mechanistically, it inhibited the PI3K/AKT and NF-κB signalling pathways.

Conclusions

The SKN-M@MN microneedle platform integrates physical skin penetration, ROS-responsive drug release, and pathway inhibition, offering an effective strategy for transdermal delivery of poorly soluble drugs in psoriasis therapy.

Schlagwörter

Stichwörter der Autor:innen

ROS-responsivemicellesmicroneedlespsoriasisshikonin

Autor:innen und Institutionen

  • School of Chinese Materia Medica, Guangdong Pharmaceutical University, Guangzhou 510006, China.
  • Guangdong Provincial Key Laboratory for Research and Evaluation of Pharmaceutical Preparations, Guangdong Pharmaceutical University, Guangzhou 510006, China.

ORCID-Profile: Haoran Cheng

Förderung

  • National Natural Science Foundation of China
  • Guangdong Natural Science Project

Zitieren

APA

Cheng, H., Dai, J., Cheng, L., Liang, H., Zhuang, Y., Xu, H., Ou, X., & Shi, J. (2026). Shikonin-Loaded ROS-Responsive Microneedles for Psoriasis Therapy: Formulation, Transdermal Delivery, and Mechanistic Evaluation. Pharmaceutics, 18(8), 939. https://doi.org/10.3390/pharmaceutics18080939

Vancouver

Cheng H, Dai J, Cheng L, Liang H, Zhuang Y, Xu H, et al. Shikonin-Loaded ROS-Responsive Microneedles for Psoriasis Therapy: Formulation, Transdermal Delivery, and Mechanistic Evaluation. Pharmaceutics. 2026;18(8):939. doi:10.3390/pharmaceutics18080939

BibTeX
@article{Cheng2026,
  author = {Cheng, Haoran and Dai, Jiaqin and Cheng, Lulu and Liang, Hao and Zhuang, Yuji and Xu, Huishan and Ou, Xingxian and Shi, Jun},
  title = {Shikonin-Loaded ROS-Responsive Microneedles for Psoriasis Therapy: Formulation, Transdermal Delivery, and Mechanistic Evaluation},
  journal = {Pharmaceutics},
  year = {2026},
  volume = {18},
  number = {8},
  pages = {939},
  doi = {10.3390/pharmaceutics18080939}
}
Kostenlos starten →